Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer

NEXT STORY
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
PREV STORY
Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer

NEXT STORY
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
PREV STORY
Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID

HAIFA, Israel, July 20, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a ...

author_avatar
NASDAQ Market News

Helikobakteeritulehdus lisää mahasyövän riskiä – väestöseulontaan osallistuneiden pitkäaikaisseuranta on saatu päätökseen

Biohit Oyj lehdistötiedote 8.4.2016 klo 16:45 paikallista aikaa (EEST) Helikobakteerin yhteydestä mahasyöpään on saatu lisää ...

author_avatar
NASDAQ Market News

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

author_avatar
NASDAQ Market News